SNPMiner Trials by Shray Alag

SNPMiner Trials: Clinical Trial Report

Report for Clinical Trial NCT00070473

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

A Phase I Study of Pemetrexed (LY231514, Alimta) in Children and Adolescents With Recurrent Solid Tumors

RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, use different ways to stop tumor cells from dividing so they stop growing or die. Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of pemetrexed disodium in treating young patients with recurrent solid tumors.

NCT00070473 Unspecified Childhood Solid Tumor, Protocol Specific

1 Interventions

Name: pemetrexed disodium

Type: Drug

Primary Outcomes

Measure: Event Free Survival

Time: Length of study

Secondary Outcomes

Description: Any patient who experiences DLT at any time during protocol therapy will be considered evaluable for toxicity. Patients not experiencing DLT must complete a full cycle of therapy to be considered potentially evaluable for toxicity. Patients who are not evaluable for toxicity will be replaced.

Measure: Dose Limiting Toxicity

Time: Length of study

Description: The MTD will be that dose at which fewer than one-third of patients experience DLT

Measure: Maximum Tolerated Dose

Time: Length of study

Purpose: Treatment

There is one SNP


1 C677T

- Correlate the presence of the C677T polymorphism of the methylenetetrahydrolate reductase gene, the presence of a polymorphism in the enhancer region of the thymidylate synthase (TS) gene promoter (2R and 3R tandem repeats), the presence of a polymorphism within one of those repeats, and the presence of a functional polymorphism in the 3'-untranslated region with toxicity in patients treated with this drug. --- C677T ---

HPO Nodes